Magnitude of Reduction in PSA Level May Indicate Outcomes in Prostate Cancer by admin_63069 | Mar 19, 2023 | Related Topics Greater depth of prostate-specific antigen (PSA) decline is associated with improved clinical outcomes among men treated with enzalutamide for nonmetastatic castration-resistant prostate cancer, according to a study published in the March issue of The Journal of Urology.